Treatment and outcomes of patients with suspected HIT
| Treatment/outcomes . | HIT negative . | HIT positive . | Missing data . | |
|---|---|---|---|---|
| H/PF4-ab negative . | H/PF4-ab positive . | HIPA positive . | ||
| Treatment | ||||
| IVIG, n (%) | 30 (2.6) | 0 (0.0) | 6 (5.1) | 34 (2.4) |
| Alternative anticoagulant started, n (%) | 111 (9.3) | 65 (89.0) | 112 (94.1) | 11 (0.7) |
| Argatroban, n (%) | 43 (3.6) | 47 (64.4) | 83 (69.7) | |
| Bivalirudin, n (%) | 5 (0.4) | 5 (6.8) | 12 (10.1) | |
| Danaparoid, n (%) | 2 (0.2) | 0 (0.0) | 0 (0.0) | |
| Fondaparinux, n (%) | 40 (3.3) | 9 (12.3) | 14 (11.8) | |
| Rivaroxaban, n (%) | 15 (1.2) | 2 (2.7) | 9 (7.6) | |
| Apixaban, n (%) | 6 (0.5) | 3 (4.1) | 2 (1.7) | |
| Edoxaban, n (%) | 3 (0.2) | 1 (1.4) | 1 (0.8) | |
| Dabigatran, n (%) | 0 (0.0) | 0 (0.0) | 1 (0.8) | |
| Others, n (%) | 2 (0.2) | 1 (1.4) | 4 (3.4) | |
| Outcomes | ||||
| Platelet recovery, n (%) | 53 (3.8) | |||
| Not recovered | 159 (13.8) | 6 (8.5) | 7 (6.2) | |
| Partially recovered | 303 (26.2) | 25 (35.2) | 19 (16.8) | |
| Fully recovered | 694 (60.0) | 40 (56.3) | 87 (77.0) | |
| Platelets at follow-up, median (IQR), ×109/L | 162 (86-274) | 194 (120-350) | 203 (110-280) | 28 (2.0) |
| Venous thromboembolism, n (%) | 66 (5.6) | 8 (11.3) | 27 (23.1) | 30 (2.2) |
| Arterial thromboembolism, n (%) | 55 (4.7) | 6 (8.5) | 11 (9.4) | 30 (2.2) |
| Major bleeding, n (%) | 159 (13.4) | 6 (8.2) | 15 (12.6) | 13 (0.9) |
| Death, n (%) | 260 (21.7) | 11 (15.1) | 21 (17.6) | 1 (0.1) |
| Treatment/outcomes . | HIT negative . | HIT positive . | Missing data . | |
|---|---|---|---|---|
| H/PF4-ab negative . | H/PF4-ab positive . | HIPA positive . | ||
| Treatment | ||||
| IVIG, n (%) | 30 (2.6) | 0 (0.0) | 6 (5.1) | 34 (2.4) |
| Alternative anticoagulant started, n (%) | 111 (9.3) | 65 (89.0) | 112 (94.1) | 11 (0.7) |
| Argatroban, n (%) | 43 (3.6) | 47 (64.4) | 83 (69.7) | |
| Bivalirudin, n (%) | 5 (0.4) | 5 (6.8) | 12 (10.1) | |
| Danaparoid, n (%) | 2 (0.2) | 0 (0.0) | 0 (0.0) | |
| Fondaparinux, n (%) | 40 (3.3) | 9 (12.3) | 14 (11.8) | |
| Rivaroxaban, n (%) | 15 (1.2) | 2 (2.7) | 9 (7.6) | |
| Apixaban, n (%) | 6 (0.5) | 3 (4.1) | 2 (1.7) | |
| Edoxaban, n (%) | 3 (0.2) | 1 (1.4) | 1 (0.8) | |
| Dabigatran, n (%) | 0 (0.0) | 0 (0.0) | 1 (0.8) | |
| Others, n (%) | 2 (0.2) | 1 (1.4) | 4 (3.4) | |
| Outcomes | ||||
| Platelet recovery, n (%) | 53 (3.8) | |||
| Not recovered | 159 (13.8) | 6 (8.5) | 7 (6.2) | |
| Partially recovered | 303 (26.2) | 25 (35.2) | 19 (16.8) | |
| Fully recovered | 694 (60.0) | 40 (56.3) | 87 (77.0) | |
| Platelets at follow-up, median (IQR), ×109/L | 162 (86-274) | 194 (120-350) | 203 (110-280) | 28 (2.0) |
| Venous thromboembolism, n (%) | 66 (5.6) | 8 (11.3) | 27 (23.1) | 30 (2.2) |
| Arterial thromboembolism, n (%) | 55 (4.7) | 6 (8.5) | 11 (9.4) | 30 (2.2) |
| Major bleeding, n (%) | 159 (13.4) | 6 (8.2) | 15 (12.6) | 13 (0.9) |
| Death, n (%) | 260 (21.7) | 11 (15.1) | 21 (17.6) | 1 (0.1) |
This table summarizes treatment strategies and clinical outcomes in patients with suspected HIT (n = 1393). Patients were stratified into 3 groups: (1) HIT-negative without heparin/PF4 antibodies, (2) HIT-negative with heparin/PF4 antibodies, and (3) HIT-positive, defined by a positive washed-platelet HIPA test. Results are grouped by final diagnosis, which was not available at the time of initial treatment decisions.
ab, antibody; IVIG, IV immunoglobulins.